Skip to Main Content Area
  • Event registration
  • Member Login
  • OCREB online
  • Home
  • About
  • Programs
  • Education
  • Careers
  • Contact

Annual Report 2011/12

OICR Annual Report 2011/12

OICR is an innovative translational research institute dedicated to research on the prevention, early detection, diagnosis and treatment of cancer.

Read the Annual Report: PDF [24 MB]

About

  • Annual Reports
  • Board of Directors
  • Careers
  • Corporate Fact Sheet
  • Executives
  • Media Centre
  • News
  • OICR Investigators
  • OICR Slide Deck
  • Scientific Advisory Board
  • Staff Directory
  • Strategic Plan

Programs

  • Innovation Programs
  • Cancer Stem Cells
  • Immuno- and Bio-therapies
  • Innovation in Target Validation (Terry Fox Research Institute, Ontario Node)
  • Smarter Imaging
  • Ontario Health Study
  • Technology Programs
  • Drug Discovery
  • Genetic Epidemiology and Biostatistics
  • Genome Technologies
  • Informatics and Bio-computing
  • Imaging Translation
  • Transformative Pathology
  • Translation Programs
  • Commercialization
  • Health Services Research
  • High Impact Clinical Trials
  • Other
  • Funding opportunities and research grants
  • Ontario Tumour Bank
  • Ontario Cancer Research Ethics Board (OCREB)
Close
Home → About OICR → News → Cancer News for June 4, 2012
  • News
    • News Releases
    • Portal Newsletter
    • Commercialization
    • OICR in the News
    • Cancer News

Media Contact

  • Christopher Needles
  • Manager, Editorial Services and Media Relations
  • christopher [dot] needlesatoicr [dot] on [dot] ca
  • Telephone: 416-673-8505
Syndicate contentSubscribe to all news items
  • Visit the Media Centre
  • Back to About OICR

Cancer News for June 4, 2012

June 4, 2012 In: Cancer News

  • Antibodies
    Antibodies Slow Progress of Advanced Cancer
    From medpge today
  • Bioinformatics
    Researchers create powerful new tool for research and drug development
    From Medical Xpress
  • Brain cancer
    Mutations Key to Chemo in Brain Tumor
    From medpage today
  • Breast cancer
    Early RT Hikes Risk for Breast Cancer
    From medpage today
  • Breast cancer
    In Study, Drug Delays Worsening of Breast Cancer, With Fewer Side Effects
    From the New York Times
  • Breast cancer
    New Cancer Data Shine Spotlight On The Secret Committees That Make Medicine's Toughest Decisions
    From Forbes
  • Drug development
    Nearly 1,000 cancer drugs in development in USA
    From Pharma Times Online
  • Drug development
    FDA to let women try new breast drugs earlier
    From the Chicago Tribune
  • Immunotherapy
    Drug Helps Defense System Fight Cancer
    From the New York Times
  • Informed consent
    Columbia Researchers Developing Informed Consent Guidelines for Return of Sequencing Results
    From GenomeWeb Clinical Sequencing News
  • Prostate cancer
    Interrupting Prostate Cancer Treatment Could Shorten Life, Study Finds
    From the New York Times
Permalink

About

  • Annual Reports
  • Board of Directors
  • Careers
  • Corporate Fact Sheet
  • Executives
  • Media Centre
  • News
  • OICR Investigators
  • OICR Slide Deck
  • Scientific Advisory Board
  • Staff Directory
  • Strategic Plan

Programs

  • Innovation Programs
  • Cancer Stem Cells
  • Immuno- and Bio-therapies
  • Innovation in Target Validation (Terry Fox Research Institute, Ontario Node)
  • Smarter Imaging
  • Ontario Health Study
  • Technology Programs
  • Drug Discovery
  • Genetic Epidemiology and Biostatistics
  • Genome Technologies
  • Informatics and Bio-computing
  • Imaging Translation
  • Transformative Pathology
  • Translation Programs
  • Commercialization
  • Health Services Research
  • High Impact Clinical Trials
  • Other
  • Funding opportunities and research grants
  • Ontario Tumour Bank
  • Ontario Cancer Research Ethics Board (OCREB)
  • Event Registration
  • Member Login
  • Links
  • Sitemap
  • Terms and Conditions
  • Policies and Procedures

© 2013 Ontario Institute for Cancer Research. All rights reserved.

The Government of Ontario

Funding for the Ontario Institute for Cancer Research
is provided by the Government of Ontario